|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on January 2, 2003; DOI 10.1182/blood-2002-08-2382.
RED CELLS
From the Department of Human Nutrition and Metabolism,
Hebrew University Hadassah Medical School, Jerusalem; Department of
Biological Chemistry, Institute of Life Sciences, Jerusalem; Department
of Medicine, Shaare Zedek Medical Center, Hebrew University of
Jerusalem, Israel; and Lady Davis Institute for Medical
Research, Montreal, Quebec, Canada.
Although iron chelation therapy with deferoxamine (DFO) results in
improved life expectancy of patients with thalassemia, compliance with
parenteral DFO treatment is unsatisfactory, underlining the need for
alternative drugs and innovative ways of drug administration. We
examined the chelating potential of pyridoxal isonicotinoyl hydrazone
(PIH) analogs, alone or in combination with DFO, using hypertansfused
rats with labeled hepatocellular iron stores and cultured iron-loaded
rat heart cells. Our in vivo studies using 2 representative PIH
analogs, 108-o and 109-o, have shown that PIH analogs given orally are
2.6 to 2.8 times more effective in mobilizing hepatocellular iron in
rats, on a weight-per-weight basis, than parenteral DFO administered
intraperitoneally. The combined effect of DFO and 108-o on
hepatocellular iron excretion was additive, and response at a dose
range of 25 to 200 mg/kg was linear. In vitro studies in heart cells
showed that DFO was more effective in heart cell iron mobilization than
all PIH analogs studied. Response to joint chelation with DFO and PIH
analogs was similar to an increase in the equivalent molar dose of DFO alone, rather than the sum of the separate effects of the PIH analog
and DFO. This finding was most likely the result of iron transfer from
PIH analogs to DFO, a conclusion supported directly by iron-shuttle
experiments using fluorescent DFO. These findings provide a rationale
for the combined, simultaneous use of iron-chelating drugs and may have
useful, practical implications for designing novel strategies of iron
chelation therapy.
(Blood. 2003;101:4172-4179) Iron chelation therapy with deferoxamine (DFO)
results in a significant improvement in well-being and life expectancy
of thalassemic patients with transfusional iron overload.1
This is largely attributed to the prevention of heart disease in most
well-treated subjects and to the reversal of existing heart disease in
some patients through vigorous intravenous DFO therapy.2-4
However, compliance with the rigorous requirements of parenteral DFO
treatment is far from satisfactory, and the failure to achieve negative iron balance in a substantial proportion of patients5
underlines the need for the development of alternative drugs and for
innovative ways of drug administration.
Interest in the combined use of chelators has been stimulated by
metabolic balance studies performed in thalassemic patients in whom the
coadministration of deferiprone (L1) and DFO resulted in higher iron
excretion rates than the administration of DFO alone.6 The
term "shuttle effect" was coined by Grady and
Giardina,6 implying that the combination of a weak
chelator with high cell penetration or of a strong chelator with poor
cell penetration but efficient excretion may result in an improved
effect through iron shuttling between the 2 compounds. In the present
study, we wanted to explore the mechanism of combined chelation
treatment using DFO and a family of orally effective iron
chelators In vivo studies
Chelators
Counting methods
Preparation of radioiron label In vivo 59Fe-labeled ferritin was prepared by injecting 100 to 200 µCi (0.37-0.72 MBq) 59Fe-citrate, at a citrate-to-iron ratio exceeding 40:1, into rats that had been given 12 mg iron dextran the preceding week. Animals were killed 24 hours later, and purified radioactive ferritin was prepared by the method of Bjorklid and Helgeland.13 Initial processing of the storage iron label has been described in detail in previous communications.14-17 Total levels of nonheme iron in the livers were determined by the method of Torrance and Bothwell.18Design of animal studies These studies were approved by the institutional committee for animal experimentation of the Hebrew University Hadassah Medical School. All studies were performed in hypertransfused animals. Hypertransfused rats were housed in metabolic cages, and stool and urine were collected for 7 consecutive days. One hour after the intravenous injection of radioiron-labeled ferritin on day 0, a single 200 mg/kg dose of chelator was administered intraperitoneally (DFO) or orally (PIH analogs). In all experiments, each subgroup of control or treated animals consisted of at least 4 subjects. All animals were killed on day 7, and the organ distribution of radioiron was determined as described above. Whole-body radioactivity was determined on day 0 (representing 100% initial radioactivity) and day 7 to determine total radioiron excretion. This measurement was used as an independent confirmation of total radioiron excretion based on the measurement of cumulative fecal and urinary radioiron excretion. For the statistical evaluation of differences between treatment groups, the Student t test has been used.In vitro studies Cell cultures. Cultures from 1-day-old rats (Hebrew University strain) were obtained by methods described in detail in our previous studies.11,19-23 Combined fractions of heart cells were resuspended in growth medium into a sterile 250-mL flask (Nunc; Nunclon Delta, Herlev, Denmark) through a sterile mesh to exclude explants. To reduce the number of fibroblasts and increase the proportion of myoblasts, a preplating method was used exploiting the faster attachment of fibroblasts to the dish surface.24 After 1 hour of preplating at 37°C in 100-mm diameter Petri dishes, the pooled cells were diluted in growth medium to a density of 9 × 105 to 1 × 106 cells/mL and were seeded into a 35-mm diameter Petri dish (Falcon 3001; Falcon Labware, Oxnard, CA). After 24 to 36 hours, this concentration yielded an almost confluent layer of beating heart cells at a final density of approximately 2 × 106 cells. Cultures were kept at 37°C in an atmosphere of 5% CO2 and 95% air. Experiments were performed at 5 days of culture, when more than 80% of the cells were beating myocardial cells. Continued viability of cultured iron-loaded cells was documented by supravital dye exclusion and by the absence of enzyme (lactate dehydrogenase) leakage into the culture medium after 24-hour iron loading. For the chelating studies, DFO or PIH analogs were dissolved in serum-free medium to a final concentration of 0.25% or less. Radioactive iron labeling. 59Fe-citrate (specific activity, 3-20 µCi [0.111-0.74 MBq]/µg; Amersham Radiochemical Centre, Amersham, England) was mixed with sufficient sterile ferric ammonium citrate (BDH Fine Chemicals, Poole, England) to provide a concentration of 100 µg/mL elemental iron. In all studies a final concentration of 160 µM iron was used for iron loading and radioiron labeling of heart cell cultures. To terminate incubations, the culture plates were washed twice with 1-mL cold culture medium. Cells were scraped and transferred into counting tubes by means of a rubber policeman and were resuspended in 0.5 mL culture medium. 59Fe activity was determined in an automatic well-type scintillation counter (Packard Instruments). Iron shuttle studies. Fluorescein-DFO (Fl-DFO; F-6877) was purchased from Molecular Probes (Eugene, OR). Clear plastic, flat-bottomed, 96-well plates were used (F96 Maxisorp; Nunc, Roskilde, Denmark). HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid)-buffered-saline (HBS; 150 mM NaCl, 20 mM HEPES, pH 7.3). The fluorescence of Fl-DFO was determined in a multiwell plate reader (BMG LabTechnologies, Offenburg, Germany) with excitation and emission filters of 485 and 538 nm, respectively, and gain of 20 nm. Complexes of 108-o:Fe were formed by mixing FeNTA (5 mM ferrous ammonium sulfate:35 mM NTA [nitriloacetate]) and 108-o in HBS to yield solutions containing 10 µM Fe and increasing concentrations of 108-o to 500 µM, followed by incubation for 1 hour at room temperature. At 0 minute, 25 µL each chelator-Fe complex was mixed with 100 µL of 2.5 µM Fl-DFO in HBS, and fluorescence was monitored over time in a fluorescence plate reader. In our previous studies, we showed that DFO and its fluorescein derivative, Fl-DFO, have similar Fe-binding affinities and that Fl-DFO provides a valid model for native DFO.25 Evaluation of cotreatment.
Quantitative analysis of the dose-response profiles of a combination of
drugs was based on the methods described by Pöch et
al.26-28 Parameter values of dose-response curves were
calculated by fitting the sigmoidal 4-parameter logistic function
y = [(a
Studies in hypertransfused rats DFO- or PIH-class compounds alone. In untreated controls, total body radioactivity 7 days after labeling was 88.9% ± 1.8% of the injected dose. Of this, 79.9% ± 9.4% was in the liver, 1.5% ± 0.7% was in circulating red blood cells, 0.5% ± 0.1% was in the spleen, and 7.0% ± 0.3% was in residual tissues. The injection of a single dose of 200 mg/kg DFO resulted in a decrease in whole-body radioactivity from 88.9% ± 1.8% to 69.8% ± 3.8% (P < .001) and after an identical oral dose of 108-o to 37.5% ± 2.1% and of 109-o to 33.8% ± 7.5% (P < .001). This was accompanied by a decrease in liver radioactivity from 79.9% ± 9.4% to 55.5% ± 5.5% (P < .001) following DFO to 30.6% ± 5.5% following 108-o and to 26.4% ± 4.2% following 109-o (P < .001). Thus, practically all chelator-induced radioiron excretion could be accounted for by the loss of hepatic radioactivity. Recovery of radioactivity in the stool collected over 7 days accounted for 97.1% ± 4.3% of radioiron excretion. By contrast, urinary radioiron excretion was less than 1% in all experiments performed. Response to 108-o and 109-o, as manifested by a decrease in whole body radioactivity and liver radioactivity, was clearly greater with 108-o and 109-o than with DFO (P < .001). Variations in blood, spleen, and residual radioactivity in the chelator-treated groups compared with untreated controls were minimal. Dose-response and combined therapy. In the second part of our in vivo studies in hypertransfused 59Fe-ferritin-tagged animals, we explored the effect of increasing doses of oral 108-o administered separately or in combination with a fixed dose (100 mg/kg) of parenteral DFO (Figure 2A-B). As seen in Figure 2A, 108-o-induced radioiron excretion was linearly dose-related and ranged from 2.3% ± 1.8% at 25 mg/kg to 42.6% ± 7.7% at 200 mg/kg. By comparison, net radioiron excretion following a single 100 mg/kg dose of DFO was 17.5% ± 1.6%. A mirror image of this response can be seen in Figure 2B describing the decrease in residual hepatic radioactivity.
Combined 108-o and DFO treatment was more efficient than either drug given alone. This effect was most prominent (P < .001) at the highest 108-o dose levels studied, namely 200 mg/kg for net radioiron excretion and 100 to 200 mg/kg for the decrease in residual hepatic radioactivity. The magnitude of this combined response was roughly equal to the combined effects of each drug given alone, supporting an additive effect of combined treatment. Studies in cultured heart cells The ability of DFO and PIH analogs (identified by their numbers in Table 1) to inhibit the uptake of radoioiron by cultured heart cells is described in Table 2. Five-day-old rat heart cell cultures were exposed for 24 hours to 160 µM iron supplied as ferric ammonium citrate alone (controls) or in the presence of various chelators, at concentrations ranging from 0 to 320 µM. Washed control cells had a radioiron uptake of 29.6% ± 2.6% of the total radioactivity in the iron-loading culture medium. In the case of compounds 108, 109, and 208, both ortho- and para-substituted isomers have been studied.
As shown in Table 2, some of the analogs had no ability to inhibit
radioiron uptake. These included para-108 and para-208 and compounds
301, 308 309, 311, and 315. All other compounds showed a dose-related
inhibition of heart cell iron uptake, with DFO the most effective.
Because DFO is a hexadentate chelator combining with iron at a 1:1
molar ratio, whereas all others are tridentate requiring 2 M chelator
to bind 1 M iron, a better comparison of chelating ability is offered
by presenting results according to iron-binding equivalents (Figure
3). This showed that the prevention of
iron uptake was complete, or near complete, for all effective chelators
at an iron-binding equivalent concentration of 160 µM, identical with
the concentration of iron present in the incubation mixture.
The ability of DFO and PIH analogs to remove iron from iron-loaded
heart cells was studied next. Heart cell cultures were exposed for 24 hours to 160 µM iron supplied as ferric ammonium citrate, washed, and
treated subsequently for another 24 hours with DFO or a PIH analog, at
concentrations ranging from 0 to 320 µM (Figure
4).
As shown in Figure 4, the ability of DFO to remove heart cell radioiron
was substantially better than that of PIH and its analogs, at all
concentrations studied. This advantage of DFO over the other compounds
remained significant (P < .001), even when allowance was
made for the difference in iron-binding capacity (ie, PIH analogs at
twice the molar concentration of DFO). The effect of combined DFO and
PIH analog treatment performed in the same experimental system is shown
in Figure 5.
As shown previously (Figure 4), in all cases DFO was more effective than the corresponding PIH analog at equimolar concentrations ranging from 40 to 320 µM. Cotreatment with both chelators (DFO + analog I) resulted in a response that was significantly (P < .001) greater than that of either drug alone over the concentration range 80 to 320 µM. However, such cotreatment involved the use of twice the molar concentration of each drug used separately. Hence, a more appropriate comparison was to examine the effect of combined treatment consisting of equal parts of both chelators at half the molar concentration of the single drug (DFO + analog II). This method of comparison revealed an interesting phenomenon: at molar concentrations of 160 to 320 µM, a crossover effect was obtained with all analogs studied, wherein the effectiveness of DFO + analog became equal to or even exceeded that of DFO. This finding, encountered with all analogs studied, did not support a simple additive effect in which the expected result should be intermediate between the effect of each chelator alone. To examine in a more comprehensive manner whether the interaction
between DFO and the PIH analogs was additive or independent, additional
studies have been performed using constant (20 or 40 µM)
concentrations of DFO in the presence of various concentrations of the
PIH analog 108-o, ranging from 0 to 160 µM (Figure
6). Dose-response profiles of the
combination of drugs was subjected to quantitative analysis based on
the methods described by Poch et al.26-28 Five-day-old
cultures were first incubated with 160 µM 59Fe-labeled
ferric ammonium citrate for 24 hours, washed, and exposed for another
24 hours to 20 or 40 µM DFO and 0 to 160 µM 108-o. The effect was
described as percentage of initial radioactivity in control
iron-loaded cells.
As shown in Figure 6, a significant deviation from dose additivity was obtained for the 2 combinations of 108-o and DFO using the 95% confidence limit with upper and lower boundaries, as described by Holzmann et al.28 To document the ability of DFO to remove iron bound to PIH analogs (the
shuttle effect), we exploited the phenomenon of fluorescence quenching
when iron is bound to fluorescein-DFO (Fl-DFO). Fl-DFO (2 µM) was
added to preformed analog-Fe complexes containing a fixed Fe
concentration (2 µM) with increasing concentrations of the PIH analog
108-o. PIH analog-Fe ratios ranged from 1.56:1 to 50:1. The transfer
of iron from 108-o to DFO at a 108-o concentration of 3.12 µM was
compete within less than 10 minutes, as indicated by the quenching of
fluorescence (Figure 7). Although at higher molar ratios
108-o was able to slow down the transfer of Fe to Fl-DFO in a
concentration-dependent manner, it was unable to prevent it even when
the molar ratio of 108-o to Fl-DFO was
50:1.
In view of the failure of iron chelation treatment with DFO to achieve the goals of iron depletion in a substantial proportion of patients with thalassemia,5 alternative methods of treatment have been explored with other orally active chelators. Studies using the oral chelator deferiprone (L1) have indicated6 that combined DFO and L1 treatment may be more effective than either drug alone. In addition, it may decrease their toxic side effects, some of which are dose related. However, the use of deferiprone is associated with an increased risk for agranulocytosis and other complications.29-31 Hence, it would be interesting to validate the concept of increased efficacy of combined chelation treatment using other orally effective chelators of potential clinical value. Pyridoxal isonicotinoyl hydrazone (PIH) was first introduced by Ponka et al in 1979, demonstrating its ability to mobilize iron from 59Fe-labeled reticulocytes.7 PIH is a tridentate chelator with a molecular weight of 287 (Figure 1). At physiologic pH levels, PIH is mainly in its neutral form, which allows access across cell membranes and absorption from the gut. At pH 7.4 and a ligand concentration of 1 mM, the pM value of PIH is 27.7, which is less than 28.6 for DFO.8,9,32 The selectivity of PIH for iron is comparable with that of DFO. Studies in rats33,34 have shown that PIH is able to remove parenchymal and reticuloendothelial (RE) iron and that practically all chelated iron is excreted through the bile.34 Its in vivo chelating efficiency in rats was equal to, or slightly better than, DFO, and there was no evidence of toxicity at doses up to 500 mg/kg per day. Various PIH analogues have been prepared and evaluated by Richardson and Ponka9 and Baker et al.32 Some of these, such as the pyridoxal-benzoyl hydrazones, are as much as 280% more effective than PIH, a feature largely attributed to their greater lipophilicity. Unfortunately, studies in patients with iron overload treated with PIH at a dose of 30 mg/kg per day have shown only a modest net iron excretion of 0.12 ± 0.07 mg/kg per day,35 which is less than the mean value of 0.5 mg/kg per day usually required to achieve negative iron balance. Although the results of this pilot study in thalassemic patients were generally regarded as evidence for the limited value of PIH in the treatment of thalassemia, several arguments have been raised in favor of PIH. First, the dose of 30 mg/kg used in the above study was less than the effective dose of 125 to 500 mg/kg used in experimental animals. Second, PIH was given to patients after calcium carbonate as a powder in gelatin capsules. This might have prevented acid hydrolysis of PIH, but it also could have drastically limited its absorption because of the low solubility of PIH in aqueous solution at a neutral pH level.32,36 In view of the uncertainty regarding the ability of PIH to induce satisfactory iron excretion as a single drug, we wanted to explore the possible advantage of combined chelation treatment consisting of PIH analogs and DFO using in vivo and in vitro animal models. In these studies, we sought to determine whether the coadministration of PIH analogs and DFO may result in an additive, or an even stronger, effect. In our in vivo studies, we have selectively labeled hepatocellular iron stores with 59Fe-ferritin to document the effect of iron chelation on storage iron mobilization. The aim of hypertransfusion was to minimize the recycling of storage iron onto circulating transferrin. These studies comparing the in vivo effects of DFO and 2 representative PIH analogs, 108-o and 109-o, allow the following conclusions to be drawn. PIH analogs given orally are 2.6 to 2.8 times more effective in rats, on a weight-per-weight basis, than parenteral DFO in promoting the excretion of storage iron from parenchymal iron stores. The combined effect of DFO and 108-o on hepatocellular storage iron excretion was additive. The dose-response obtained with 108-o at a dose range of 25 to 200 mg/kg was linear, and there was no suggestion of a diminishing response at the highest dose studied. The effect of combined chelation treatment was further explored in
cultured iron-loaded heart cells. Unlike the studies performed in
intact animals, this in vitro model offered accurate control of
experimental conditions, such as the degree of iron overload and
extracellular drug concentrations. Results showed that the chelators
studied, including DFO and a large number of PIH analogs, are equally
effective in preventing the uptake of nontransferrin-bound iron from
the culture medium. This effect was directly related to their
iron-binding capacity requiring a 2:1 molar ratio of drug to iron for
all tridentate PIH analogs and a 1:1 ratio for the hexadentate
chelator, DFO. However, when iron loading preceded chelating treatment
to study the mobilization of intracellular iron, DFO was more effective
than the PIH analogs. This difference cannot be attributed to better
cell penetration of DFO because previous studies in hepatocytes and
reticulocytes have documented the excellent ability of the small
lipophilic PIH class molecules to enter cells compared with the more
limited cellular penetration of DFO.8,9,37 An alternative,
and more likely, explanation In line with our previous in vivo experiments, in vitro cotreatment of heart cells with DFO and PIH analogs had an improved iron-mobilizing effect. To analyze the dose-response profiles of the drug combinations used, we followed the methods described by Poch et al.26-28 The use of model combination effects for the delineation of sites and mechanisms of action requires some understanding of the underlying bases of these models. The dose-additivity model describes the combination effects of agents that share the same molecular site of action. Agents that compete for the same binding site are then expected to exhibit a dose-additive combination, which can be seen as a special case of competitive interaction. Applying this model for the evaluation of chelating agents means that 2 agents acting at the same molecular site of action should behave according to the model of dose-additivity. On the other hand, any significant deviation from this model suggests either different sites of action of the compounds tested in combination or a dual action of one component or both agents. Interaction between a dual-action compound and another agent with 1 of the 2 components is likely to result in a combination effect different from a pure competitive action. Because the combined effect of the 2 chelators was significantly greater than dose-additive, we wanted to explore the possibility of a shuttle effect wherein iron first chelated by PIH analogs is transferred subsequently to DFO. Our study using fluorescent DFO (Fl-DFO) provides direct evidence for the transfer (shuttling) of iron from 108-o to DFO, manifested in the quenching of fluorescence when iron prebound to 108-o is transferred to Fl-DFO. This transfer was rapid and complete within less than 10 minutes in the presence of roughly equal molar concentrations of the 2 chelators. Although this transfer did slow down in a concentration-dependent manner, it was not prevented even by a 108-o/Fl- DFO ratio of 50:1. In attempting to evaluate the implications of the present findings, one should take account of the limitations of the experimental systems used: Dose and delivery of the 2 chelators Although both compounds were given at an identical dose of 200 mg/kg in vivo, the molar dose of DFO (molecular weight [MWt] 657) was less than half that of PIH (MWt 287). However, on a weight-per-weight basis, the iron-binding equivalent of the tridentate PIH analog chelators was roughly identical to that of the hexadentate chelator DFO. Although DFO was given parenterally and PIH analogs were administered by gastric gavage, these methods of delivery, along with dosimetry relying on weight per kilogram rather than on molarity, are identical with the methods accepted in clinical practice for evaluating chelating drugs. However, the single intraperitoneal injection of DFO might have been less effective than the continuous subcutaneous infusion used in clinical practice.Use of selective storage iron labels This allowed identification of specific chelatable storage iron pools interacting with chelators. However, this method may overlook other chelatable pools such as nontransferrin-bound plasma iron (NTBI) derived largely from RE cells.4 In the present studies we did not use a selective RE iron label, such as heat-damaged red blood cells (RBCs), because our previous study of PIH has already shown that labeled RE iron does not contribute greatly to PIH-induced iron excretion.34 Conversely, first-pass interaction of oral PIH-class chelators with hepatocellular iron stores through the portal circulation might have led to overestimation of their efficacy compared with parenteral DFO, of which only a fraction may reach the liver. This difference, however, is identical to the clinical setting wherein oral PIH analogs (unlike DFO) are first presented to hepatocytes through the portal circulation. Thus, our estimates of the relative efficacy of PIH analogs compared with DFO may be distorted by the methodology used and should be interpreted with caution. We did not document DFO-induced iron excretion derived from RBC catabolism in the RE system, a major source of chelated iron in the clinical context. In addition, a single intraperitoneal injection of DFO might have been less effective than the continuous subcutaneous infusion used in clinical practice.In vitro studies in cultured heart cells Results of these studies showing a lower efficiency of PIH analogs appear to conflict with the results of our in vivo experiments in which 108-o and 109-o were more effective than DFO on a weight-per-weight basis. This may reflect a genuine difference in the organ specificity of DFO compared with PIH analogs. Previous studies in macrophages, reticulocytes, and hepatocytes have shown that hepatocytes are particularly responsive to pyridoxal hydrazone chelators.38 This may be explained by the unique ability of hepatocytes to secrete chelated iron through the bile instead of relying on the limited ability of the intracellularly chelated iron complex to cross the plasma membrane.Having considered all these caveats, it is still possible to arrive at some significant conclusions on the joint effects of DFO and PIH analogs based on results of the present studies. Simultaneous administration of DFO and PIH analogs results in an increase in chelating effect that is additive in hepatic iron excretion but higher than additive with respect to myocardial iron mobilization. In the rat heart cell model used by us, the magnitude of this joint effect is similar to an increase in the equivalent molar dose of DFO alone, rather than the sum of the separate effects of PIH analog and DFO. This finding is probably the result of a transfer of chelated iron from PIH analogs to DFO, a conclusion supported directly by the results of our experiments using fluorescent DFO. Our conclusion is also supported by the results of previous studies showing that at physiologic pH 7.4, the pM value of DFO is higher than that of PIH.39 Our in vivo findings are also consistent with clinical observations in patients receiving combined treatment with DFO and the oral chelator L1, indicating that combined chelation treatment improves iron excretion in patients with thalassemia and results in a decrease in serum ferritin levels in patients who previously did not respond to standard L1 treatment.40 A number of theoretical arguments may be considered in favor of using several chelating drugs simultaneously to improve response to treatment. (1) Because the toxic side effects of the 2 compounds are different and some of them are dose dependent, it has been claimed that cotreatment may allow dose reduction and may diminish dose-related drug toxicity. However, this expectation has not been confirmed by early experience gained in clinical studies of combined DFO and deferiprone administration, and in vitro studies of non-heme iron enzyme inhibition have shown synergistic toxicity when the 2 drugs were used simultaneously.41 (2) DFO has limited access to intracellular iron stores but may be able to interact indirectly with chelated iron thanks to the shuttling effect of the small lipophilic PIH analog. Such an interaction has already been demonstrated in the context of antimalarial activity of combined DFO and PIH analog treatment.37 Such combined action may also be able to prevent the production of the toxic NTBI originating from RBC hemoglobin breakdown in the RE system.4 (3) If the shuttling concept is validated, it may be used for the coadministration of other drug combinations. For example, Grady and Giardina42 have already shown that the coadministration of deferiprone and HBED greatly enhances the oral effectiveness of HBED (N,N'-bis[2-hydroxybenzyl]-ethylenediamine-N,N'-diacetate). Likewise, our recent studies in animal models have shown a favorable interaction between ICL670A, a new orally active iron chelator designed by Novartis (Basel, Switzerland), and DFO,43 which is probably explained by an exchange of chelated iron between these 2 compounds. Although the present study offers new insights into the mechanism of combined chelation therapy, the implications of these findings to the practical management of transfusional iron overload have yet to be shown. The most serious obstacle to the introduction of new chelators for clinical use is drug safety. In this regard, the PIH analogs still require formal, detailed animal toxicity studies pending their application for treating patients. Other obstacles to the introduction of combined treatment with PIH analogs and DFO include the technical difficulty of quantitating iron excretion with PIH analogs because all such excretion is limited to the bile. In view of recent experience with ICL670, another oral chelator with exclusive biliary effect, superconducting quantum interface device (SQUID) measurement of hepatic iron concentrations may be a preferred method for documenting a negative iron balance induced by long-term chelation therapy.44 Current efforts aimed at the development of new orally effective iron chelators, such as improved hydroxypyridone derivatives,45 PIH analogs,32 and bishydroxyphenyl triazoles43,44 may allow better protection from the harmful effects of hemosiderosis and offer new directions in the management of transfusional iron overload. As shown in the present studies, the efficacy of such new drugs may be enhanced by innovative strategies of drug administration and delivery.
Submitted August 7, 2002; accepted December 29, 2002.
Prepublished online as Blood First Edition Paper, January 2, 2003; DOI 10.1182/blood-2002-08-2382.
Supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (DK54199), the Israel Science Foundation (197/99-2), and the Canadian Institutes for Health Research.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Chaim Hershko, Department of Medicine, Shaare Zedek Medical Center, PO Box 3235, Jerusalem, Israel; e-mail: hershko{at}szmc.org.il.
1. Gabutti V, Piga A. Results of long-term iron chelating therapy. Acta Haematol. 1996;95:26-36[Medline] [Order article via Infotrieve].
2.
Olivieri NF, Nathan DG, MacMillan JH, et al.
Survival of medically treated patients with homozygous
3.
Davis BA, Porter JB.
Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheteters in high-risk 4. Hershko C, Konijn AM, Link G. Iron chelators for thalassaemia. Br J Haematol. 1998;101:399-406[CrossRef][Medline] [Order article via Infotrieve]. 5. Modell B, Khan M, Darlison M. Survival in beta thalassaemia major in the United Kingdom: data from the U.K. Thalassaemia Register. Lancet. 2000;355:2051-2052[CrossRef][Medline] [Order article via Infotrieve]. 6. Grady RW, Giardina PJ. Iron chelation: rationale for combination therapy. In: Badman DG,Bergeron RJ,Brittenham GM, eds. Iron Chelators, New Development Strategies. Ponte Vedra, FL: The Saratoga Group LLC; 2000:293-310. 7. Ponka P, Borova J, Neuwirth J, Fuchs O, Necas E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta. 1979;586:278-297[Medline] [Order article via Infotrieve]. 8. Baker E, Vitolo mL, Webb JM. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochem Pharmacol. 1985;34:3011-3017[CrossRef][Medline] [Order article via Infotrieve]. 9. Baker E, Richardson DR, Gross S, Ponka P. Evaluation of the iron chelation potential of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology. 1992;15:492-501[Medline] [Order article via Infotrieve]. 10. Hershko C. Biologic models for studying iron chelating drugs. Clin Haematol. 1989;2:293-321. 11. Link G, Pinson A, Hershko C. Heart cells in culture: a model of myocardial iron overload and chelation. J Lab Clin Med. 1985;106:147-153[Medline] [Order article via Infotrieve]. 12. Edward JT, Gauthier M, Chubb FL, Ponka P. Synthesis of new acylhydrazones as iron-chelating compounds. J Chem Eng Data. 1988;33:538-540[CrossRef]. 13. Bjorklid E, Helgeland L. Sex difference in the ferritin content of rat liver. Biochim Biophys Acta. 1970;221:583-592[Medline] [Order article via Infotrieve]. 14. Hershko C, Grady RW, Link G. Phenolic ethylenediamine derivatives: a study of orally effective iron chelators. J Lab Clin Med. 1984;103:337-346[Medline] [Order article via Infotrieve]. 15. Hershko C, Cook JD, Finch CA. Storage iron kinetics, III: study of desferrioxamine action by selective radioiron labels of RE and parenchymal cells. J Lab Clin Med. 1973;81:876-886[Medline] [Order article via Infotrieve].
16.
Zevin S, Link G, Grady RW, Hider RC, Peter HH, Hershko C.
Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores.
Blood.
1992;79:248-253
17.
Rivkin G, Link G, Simhon E, Cyjon RL, Klein JY, Hershko C.
IRC11, a new synthetic chelator with selective interaction with catabolic red blood iron: evaluation in hypertransfused rats and in iron-loaded rat heart in culture.
Blood.
1997;90:4180-4187 18. Torrance JD, Bothwell TH. A simple technique for measuring storage iron concentrations in formalinized liver samples. S Afr J Med Sci. 1968;33:9-11[Medline] [Order article via Infotrieve].
19.
Hershko C, Link G, Pinson A, Peter HH, Dobbin P, Hider RC.
Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: studies in rat heart cells in culture.
Blood.
1991;77:2049-2053 20. Link G, Pinson A, Hershko C. Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. J Lab Clin Med. 1993;121:127-134[Medline] [Order article via Infotrieve]. 21. Link G, Tirosh R, Pinson A, Hershko C. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med. 1996;127:272-278[CrossRef][Medline] [Order article via Infotrieve]. 22. Link G, Saada A, Pinson A, Konijn AM, Hershko C. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells . J Lab Clin Med. 1998;131:466-474[CrossRef][Medline] [Order article via Infotrieve]. 23. Link G, Konijn AM, Hershko C. Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: mitochondrial function in cultured, iron-loaded heart cells. J Lab Clin Med. 1999;133:179-188[CrossRef][Medline] [Order article via Infotrieve]. 24. Blondel B, Roijen I, Cheneval JP. Heart cells in culture: a simple method for increasing the proportion of myoblasts. Experientia. 1971;27:356-358[CrossRef][Medline] [Order article via Infotrieve].
25.
Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI.
The assessment of serum non-transferrin iron (NTBI) in chelation therapy and iron supplementation.
Blood.
2000;95:2975-2982 26. Pöch G, Pancheva SN. Calculating slope and ED50 of additive dose-response curves and application of these tabulated parameter values. J Pharmacol Toxicol Methods. 1995;33:137-145[CrossRef][Medline] [Order article via Infotrieve]. 27. Dawson DA, Pöch G. A method for evaluating mechanistic aspects of chemical mixture toxicity. Toxicol Methods. 1997;7:267-278. 28. Holzmann S, Dittrich P, Pöch G. Dose-response curves of vasorelaxants: computerized calculation of combination effects using the example of nicorandil. J Clin Basic Cardiol. 1999;2:96-98. 29. Cohen AR, Galanello R, Piga A, DiPalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicenter study. Br J Haematol. 2000;108:305-312[CrossRef][Medline] [Order article via Infotrieve]. 30. Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002;118:330-336[CrossRef][Medline] [Order article via Infotrieve]. 31. Al-Refaie FN, Hershko C, Hoffbrand AV, et al. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol. 1995;91:224-229[Medline] [Order article via Infotrieve]. 32. Richardson DR, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med. 1998;131:306-314[CrossRef][Medline] [Order article via Infotrieve]. 33. Cikrt M, Ponka P, Necas E, Neuwirt J. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Br J Haematol. 1980;45:275-283[Medline] [Order article via Infotrieve]. 34. Hershko C, Avramovici-Grisaru S, Link G, Gelfand L, Sarel S. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J Lab Clin Med. 1981;98:99-107[Medline] [Order article via Infotrieve]. 35. Brittenham GM. Pyridoxal isonicotinoyl hydrazone: an effective iron chelation after oral administration. Semin Hematol. 1990;27:112-116[Medline] [Order article via Infotrieve]. 36. Vitolo LMW, Hefter GT, Clare BW, Webb J. Iron chelators of the pyridoxal isonicotinoyl hydrazone class, part 2: formation constants with iron(III) and iron(II). Inorg Chim Acta. 1990;170:171-174[CrossRef]. 37. Tsafack A, Loyevsky M, Ponka P, Cabantchik ZI. Mode of action of iron (III) chelators as antimalarials, IV: potentiation of desferal action by benzoyl- and isonicotinoyl-hydrazone derivatives. J Lab Clin Med. 1996;127:574-582[CrossRef][Medline] [Order article via Infotrieve]. 38. Ponka P, Richardson D, Baker E, Schulmann HM, Edward JT. Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. Biochim Biophys Acta. 1988;967:122-129[Medline] [Order article via Infotrieve]. 39. Liu ZD, Hider RC. Iron chelator chemistry. In: Templeton D, ed. Molecular and Cellular Iron Transport. New York, NY: Marcel Dekker; 2002:321-357. 40. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103:361-364[CrossRef][Medline] [Order article via Infotrieve]. 41. Kayyali R, Hider RC, Porter JB. Combined chelation using deferiprone and deferoxamine induces synergistic inhibition of non-heme iron enzymes [abstract]. Blood. 2002;100:445. 42. Grady RW, Giardina PJ. Oral iron chelation: a potential role for HBED in combination therapy [abstract]. Blood. 1999;94:3293. 43. Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G. ICL670A, a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood. 2001;97:1115-1122[Medline] [Order article via Infotrieve]. 44. Piga A, Galanello R, Cappellini MD, et al. Phase II study of oral chelator ICL670 in thalassemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics and pharmacodynamics after 6 months of therapy [abstract]. Blood. 2002;100:5. 45. Liu ZD, Liu DY, Hider RC. Synthesis, physicochemical properties and biological evaluation of aromatic ester prodrugs of 1-(2'-hydroxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP102): orally active iron chelators with clinical potential. J Pharm Pharmacol. 1999;51:555-564[Medline] [Order article via Infotrieve].
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. Whitnall, Y. S. Rahmanto, R. Sutak, X. Xu, E. M. Becker, M. R. Mikhael, P. Ponka, and D. R. Richardson The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation PNAS, July 15, 2008; 105(28): 9757 - 9762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Lim, D. S. Kalinowski, and D. R. Richardson Protection against Hydrogen Peroxide-Mediated Cytotoxicity in Friedreich's Ataxia Fibroblasts Using Novel Iron Chelators of the 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone Class Mol. Pharmacol., July 1, 2008; 74(1): 225 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sterba, O. Popelova, T. Simunek, Y. Mazurova, A. Potacova, M. Adamcova, H. Kaiserova, P. Ponka, and V. Gersl Cardioprotective Effects of a Novel Iron Chelator, Pyridoxal 2-Chlorobenzoyl Hydrazone, in the Rabbit Model of Daunorubicin-Induced Cardiotoxicity J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1336 - 1347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Kalinowski and D. R. Richardson The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer Pharmacol. Rev., December 1, 2005; 57(4): 547 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Sterba, T Simunek, Y Mazurova, M Adamcova, O Popelova, J Kaplanova, P Ponka, and V Gersl Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits Human and Experimental Toxicology, November 1, 2005; 24(11): 581 - 589. [Abstract] [PDF]
|
|
|
|
|
|
X. Xu, H. L. Persson, and D. R. Richardson Molecular Pharmacology of the Interaction of Anthracyclines with Iron Mol. Pharmacol., August 1, 2005; 68(2): 261 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Cohen, R. Galanello, D. J. Pennell, M. J. Cunningham, and E. Vichinsky Thalassemia Hematology, January 1, 2004; 2004(1): 14 - 34. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
the pyridoxal isonicotinoyl hydrazone (PIH) analogs
introduced by Ponka et al
d)/(1 + (x/c)b)] + d,
where y represents the response (in percentage) for a given
concentration x of the drug, d represents the
basal response, a represents the maximal response, b
represents the slope of the response, and c represents
ED50, the concentration of drug that elicits 50% response.
Curves of dose-additive combinations were obtained by calculating the
dose, x, of the drug, A, with which a fixed
applied dose was equi-effective. According to the definition of dose
additivity, the effects of curve A alone are to be expected at the doses of A minus x, thus providing the
y for the simulation of the corresponding additive action of
the drugs. Curves of independent combinations were calculated on the
basis of the effects, E, of drug A and drug
B alone, whereby
EA + B = EA + AB 
) or without (
) the addition of a constant (100 mg/kg)
dose of DFO. Results are expressed as net 7-day measurements
(percentage of injected radioactivity). Each treatment group consisted
of 4 animals (mean ± 1 SD).
) and presence
(
) of 20 µM (left) or 40 µM (right) deferoxamine.
Symbols and bars represent experimental mean values of triplicate
samples (± SEM). Sigmoidal fits to the experimental points are shown
by solid lines, and the theoretical dose-response curves are shown by
dashed lines (dose-additivity) and dotted lines (independent).
thalassemia.
N Engl J Med.
1994;331:574-578